Stay updated with breaking news from Hubertc chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Form DEFC14A Forte Biosciences, Inc. Filed by: Camac Fund, LP streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Metacrine (MTCR) Reports Target Patient Enrollment Achieved for MET642 Phase 2a Trial Interim Analysis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at . Metacrine, Inc.March 11, 2021 GMT SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that final results from the company’s Phase 1 trial of MET642, a farnesoid X receptor (FXR) agonist in development for the treatment of non-alcoholic steatohepatitis (NASH), will be presented as a distinguished abstract at the 2021 NASH-TAG Conference. The conference is taking place March 11-13, 2021 in Park City, Utah and virtually on-line. ....
Metacrine Reports Positive Results from Phase 1 Trial of MET642 MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase Doses Selected for Phase 2a Trial in Patients with NASH; On-Track to Initiate in 1H21 SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today reported preliminary results from its Phase 1 trial of MET642, a farnesoid X receptor (FXR) agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH) and inflammatory bowel disease. Findings show that treatment with MET642 was safe and generally well-tolerated and demonstrated a sustained pharmacokinetic (PK) profile and robust FXR target engagement after 14 days of daily oral dosing in healthy volunte ....